Literature DB >> 27881693

Outcomes of Rivaroxaban Use in Patients With Sickle Cell Disease.

Shubha Bhat, Jin Han.   

Abstract

Entities:  

Year:  2016        PMID： 27881693     DOI： 10.1177/1060028016681129

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN： 1060-0280            Impact factor:   3.154


× No keyword cloud information.
  3 in total

1.  Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.

Authors:  Megan Z Roberts; G Eric Gaskill; Julie Kanter-Washko; T Rogers Kyle; Brittany C Jones; Nicole M Bohm
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

2.  Thrombin activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell disease.

Authors:  Erica M Sparkenbaugh; Chunsheng Chen; Tomasz Brzoska; Julia Nguyen; Shaobin Wang; Gregory M Vercellotti; Nigel S Key; Prithu Sundd; John D Belcher; Rafal Pawlinski
Journal:  Blood       Date:  2020-05-14       Impact factor: 25.476

3.  Use of rivaroxaban in sickle cell disease and venous thromboembolism: A case report.

Authors:  Waail Rozi; Elrazi Awadelkarim Hamid Ali; Abdulrahman F Al-Mashdali; Mohamed Abdelrazek; Mohamed A Yassin
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.